Expanding our high-throughput ion channel screening capabilities.

Biologic modalities may offer opportunities to achieve levels of subtype selectivity that can be difficult to obtain using traditional small molecules, particularly across closely related ion channel family members. This may enable more precise modulation of disease-relevant targets while potentially reducing unwanted off-target activity.

We’re proud to introduce two scientific leaders whose expertise is helping advance ion channel drug discovery and pain research: Eddy Stevens, PhD, Chief Scientific Officer, and Tony Rush, PhD, Director of Neuroscience and Commercial Operations.

The key question is no longer whether to adopt NAMs, but how to implement them with confidence while continuing to meet evolving regulatory expectations and protecting programme value.

Charlotte Hill PhD, Senior Scientist II, explains how cardiac safety screening programmes often feel a lot like playing a game of Tetris. When timelines align, assays run well, data drops cleanly into place and clients have clear answers, there is a Tetris like satisfaction to it all.

Jacob describes his work at Metrion, the technologies he used and how they complemented his PhD research.

Tom will lead business development activities across the UK and EU, supporting Metrion’s continued growth as a global leader in ion channel drug discovery.

Thank you to our customers for their continued trust, collaboration, and partnership and the Metrion team, whose dedication, expertise, and resilience have made this an exceptional year.

Nicole describes her work at Metrion, the technologies she used and how they complemented her PhD research.

As we approach the close of our 10th anniversary year, we reflect on how far Metrion has come, from its scientific roots to becoming a trusted partner in ion channel drug discovery.